403,824 Shares in Halozyme Therapeutics, Inc. $HALO Purchased by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 403,824 shares of the biopharmaceutical company’s stock, valued at approximately $31,607,000.

A number of other institutional investors and hedge funds have also made changes to their positions in HALO. Measured Wealth Private Client Group LLC increased its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the last quarter. Harbour Investments Inc. grew its position in Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Clearstead Advisors LLC increased its holdings in Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 331 shares during the last quarter. Finally, Wexford Capital LP purchased a new stake in Halozyme Therapeutics during the third quarter valued at approximately $70,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 44,103 shares of company stock valued at $3,142,896. Insiders own 2.50% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several analyst reports. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $102.62 on Wednesday. The firm has a market cap of $11.65 billion, a price-to-earnings ratio of 30.63, a P/E/G ratio of 0.43 and a beta of 0.85. The firm has a fifty day moving average price of $77.89 and a 200 day moving average price of $71.92. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $104.78. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the previous year, the company earned $1.54 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.